ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1)
申请人:Denali Therapeutics Inc.
公开号:US20180353480A1
公开(公告)日:2018-12-13
The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.